Roth Capital Forecasts Stryker’s Q1 Earnings (NYSE:SYK)

Stryker Co. (NYSE:SYK) – Investment analysts at Roth Capital issued their Q1 2025 EPS estimates for Stryker in a research note issued to investors on Wednesday, January 29th. Roth Capital analyst J. Wittes expects that the medical technology company will post earnings of $2.98 per share for the quarter. The consensus estimate for Stryker’s current full-year earnings is $13.53 per share. Roth Capital also issued estimates for Stryker’s Q2 2025 earnings at $3.13 EPS, Q3 2025 earnings at $3.32 EPS, Q4 2025 earnings at $4.07 EPS, FY2025 earnings at $13.50 EPS and FY2026 earnings at $14.95 EPS.

A number of other research analysts have also issued reports on the company. Stifel Nicolaus boosted their price target on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday. UBS Group upped their price objective on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Royal Bank of Canada raised their target price on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday. Truist Financial upped their price target on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research note on Thursday. Finally, Robert W. Baird raised their price objective on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $419.37.

Stryker Stock Performance

Shares of NYSE SYK opened at $390.90 on Thursday. Stryker has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The company has a market cap of $149.02 billion, a PE ratio of 50.37, a P/E/G ratio of 2.68 and a beta of 0.95. The stock has a 50 day simple moving average of $376.56 and a 200-day simple moving average of $362.38.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.86%. During the same quarter last year, the business posted $3.46 earnings per share.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Zhang Financial LLC increased its holdings in shares of Stryker by 55.0% in the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock valued at $41,366,000 after purchasing an additional 40,784 shares during the period. Dale Q Rice Investment Management Ltd acquired a new position in Stryker in the 4th quarter valued at approximately $587,000. Berkshire Bank increased its stake in Stryker by 13.8% in the 4th quarter. Berkshire Bank now owns 8,489 shares of the medical technology company’s stock valued at $3,056,000 after buying an additional 1,030 shares during the period. PFW Advisors LLC purchased a new stake in Stryker in the 4th quarter worth approximately $1,350,000. Finally, Traynor Capital Management Inc. acquired a new stake in shares of Stryker during the 4th quarter valued at $324,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.90% of the company’s stock.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st were paid a dividend of $0.84 per share. The ex-dividend date was Tuesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker’s dividend payout ratio is currently 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.